Latest Ratios: P/E Ratio -0.3x · EV/EBITDA N/A · ROE -157.8%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $922591 | $2M | $26M | $2M | $3M | $1.2B | $7.4B | $11.3B | $4.1B | $1.8B | — |
| Enterprise Value | $-1932409 | $-725205 | $23M | $-78463 | $-4173255 | $1.2B | $7.4B | $11.3B | $4.1B | $1.8B | — |
| P/E Ratio → | -0.30 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.66 | 1.52 | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.48 | 1.16 | 13.96 | 2.61 | 0.78 | 335.37 | 3121.29 | 1664.47 | — | 92.95 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.52 | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | — | — | — | — | — | — | — | — | — |
| Operating Margin | -234.0% | -234.0% | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | -207.2% | -207.2% | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -157.8% | -157.8% | -928.4% | -529.4% | -105.8% | -128.4% | -112.5% | -839.9% | -229.9% | -220.2% | — |
| ROA | -103.8% | -103.8% | -515.3% | -238.7% | -65.7% | -103.6% | -84.7% | -385.5% | -161.4% | -109.6% | -3011.4% |
| ROIC | — | — | — | — | — | — | — | — | -761.7% | -340.8% | — |
| ROCE | -178.2% | -178.2% | -899.0% | -741.8% | -239.5% | -128.7% | -113.8% | -851.5% | -232.7% | -173.6% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.56 | -1.40 | -2.73 | -2.05 | -1.09 | -1.33 | -1.29 | — | -0.61 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -2.11 | — | — | — | — | -31.69 | -4.19 |
Net cash position: cash ($3M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.60 | 2.60 | 3.27 | 1.55 | 1.91 | 7.78 | 3.66 | 4.22 | 0.88 | 7.95 | 0.03 |
| Quick Ratio | 2.60 | 2.60 | 3.27 | 1.55 | 1.91 | 7.78 | 3.66 | 4.22 | 0.88 | 7.95 | 0.03 |
| Cash Ratio | 2.60 | 2.60 | 3.18 | 1.49 | 1.87 | 7.39 | 3.53 | 4.13 | 0.52 | 7.81 | 0.03 |
| Asset Turnover | — | 0.48 | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 43.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 43.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $3M | $13M | $141221 | $29135 | $1M | $1M | $1M | $682611 | $442329 | $589431 |
Binary Regulatory Approval Failure
According to recent market data, ATXI trades at a price-to-book ratio of 0.48, which, as reported in financial statements, suggests the market assigns little value to the company's intangible assets due to the persistent failure to secure FDA approval for its lead analgesic candidate.
The current P/S multiple of 0.66 is largely irrelevant given the lack of recurring revenue, serving more as a reflection of the company's distressed status rather than a growth-oriented valuation. Investors should interpret this discount as a clear signal that the market views the intellectual property as a high-risk option with a low probability of commercial realization.
Based on reported figures, the company's operating margin of -234.05% highlights a severe lack of earning power, as the firm continues to exhaust capital on clinical trials without the support of a commercialized product to offset its high fixed-cost structure.
The 100% gross margin observed in isolated periods is an accounting artifact of non-recurring milestone payments and should not be mistaken for operational efficiency. True earning power remains non-existent, and the company's profitability profile will likely remain deeply negative until a successful regulatory outcome allows for a transition to a commercialized revenue model.
As reported in quarterly financial statements, the company's current ratio of 1.90 indicates a tightening liquidity position, which, when compared to the historical peak of 4.30 in 2024Q2, suggests that the firm's ability to cover short-term obligations is rapidly deteriorating as cash reserves are consumed.
The lack of inventory or receivables means the current ratio is entirely dependent on cash and cash equivalents, which are dwindling. This trend warrants close monitoring, as the company appears to be approaching a point where it may lack the necessary liquidity to fund the next phase of clinical development without further dilutive financing.
Investors frequently misapply P/E and EV/EBITDA ratios to ATXI, which, as indicated by the company's pre-commercial status, obscures the reality that these metrics are meaningless for a firm that lacks recurring revenue and positive operating cash flow.
Using standard valuation multiples for this business model ignores the binary nature of clinical-stage biotech, where the value is derived from the probability-weighted success of a single asset. Analysts should instead focus on cash runway and the probability-adjusted net present value of the lead clinical program, rather than attempting to derive value from non-existent earnings.
Includes 30+ ratios · 11 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ATXI stock.
Avenue Therapeutics, Inc.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
Avenue Therapeutics, Inc.'s return on equity (ROE) is -157.8%. The historical average is -159.1%.
Based on historical data, Avenue Therapeutics, Inc. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Avenue Therapeutics, Inc. has 100.0% gross margin and -234.0% operating margin.